Research
Hormonal
Sibutramine therapy (Reduxin) improves cardiovascular parameters (systolic and diastolic blood pressure) without increasing heart rate in patients with obesity and comorbidities.
Long-term sibutramine therapy (6-12 months) under medical supervision can lower blood pressure in obese patients without raising heart rate.
ModerateSupportsMEDIUM confidence
Показано, что снижение веса тела при длительной (более шести месяцев) терапии Редуксином под контролем врача сопровождалось снижением уровня САД и ДАД и не приводило к повышению ЧСС.
Why this rating
Observational data, large sample size, but non-randomized.
Source
The strategy of obesity management: the results of All-Russian observational program “Primavera”
И. И. Дедов et al. · Obesity and metabolism · 2016
DOI 10.14341/omet2016136-44
cohort · n=98774Cited 22×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →